Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight

Area of Science:

• Endocrinology
• Nephrology
• Cardiovascular Medicine

Background:

• Primary aldosteronism (PA) involves excessive aldosterone secretion, now recognized as the leading cause of secondary hypertension.
• PA prevalence rises with hypertension severity, affecting up to 29.1% of resistant hypertension (RH) patients.
• Both PA and RH are high-risk phenotypes linked to increased cardiovascular morbidity and mortality.

Purpose of the Study:

• To elucidate the mechanisms by which aldosterone excess contributes to resistant hypertension.
• To highlight the role of aldosterone's non-classical effects in cardiovascular damage and drug resistance.
• To explain why standard antihypertensives may be ineffective in PA-associated resistant hypertension.

Main Methods:

• Review of existing literature on primary aldosteronism and resistant hypertension.
• Analysis of aldosterone's direct and indirect effects on cardiovascular and renal systems.
• Examination of the pathophysiological links between aldosterone excess and end-organ damage.

Main Results:

• Aldosterone excess causes salt retention and volume expansion via renal sodium and water reabsorption.
• Non-classical aldosterone effects include vascular remodeling, sympathetic overactivity, insulin resistance, and adipose tissue dysfunction.
• Aldosterone promotes oxidative stress, fibrosis, and inflammation, exacerbating end-organ damage and hypertension severity.

Conclusions:

• Aldosterone excess is a key driver of resistant hypertension and associated cardiovascular risks.
• The multifaceted actions of aldosterone contribute to a vicious cycle of worsening hypertension and end-organ damage.
• Standard antihypertensive drugs often fail to address the specific mechanisms of PA-driven hypertension and damage.